You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS1 Positive Non-Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)

Recruiting
  • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's hospital
May 31, 2022

NSCLC Trial in Guangzhou (TGRX-326)

Recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 29, 2022

Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)

Recruiting
  • Non-Small-Cell Lung Cancer
  • NSCLC
  • Nagoya, Aichi, Japan
  • +2 more
Jul 21, 2022

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 9, 2022

    Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

    Recruiting
    • Non Small Cell Lung Cancer Metastatic
    • Aix-en-Provence, France
    • +38 more
    Aug 9, 2022

    Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)

    Completed
    Has Results
    • Lung Cancer, Nonsmall Cell
    • Aurora, Colorado
      University of Colorado Denver
    Jan 19, 2022

    Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

    Recruiting
    • Nsclc
    • +5 more
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 25, 2021

    Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

    Recruiting
    • Locally Advanced or Metastatic Solid Tumors
    • Locally Advanced or Metastatic Non-small Cell Lung Cancer
    • XZP-5955 tablets
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    May 17, 2022

    NSCLC Trial in Italy (Lorlatinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Meldola, Forlì- Cesena, Italy
    • +19 more
    Jul 13, 2021

    ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

    Active, not recruiting
    • ALK or ROS1-positive NSCLC
    • Fuzhou, Fujian, China
    • +9 more
    Aug 30, 2022

    Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

    Recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • +4 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jan 8, 2023

    Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma Trial in Ancona (No suction EBUS-TBNA, Passive suction through

    Not yet recruiting
    • Mediastinal Lymphadenopathy
    • +9 more
    • No suction EBUS-TBNA
    • +2 more
    • Ancona, Italy
      Pulmonary Diseases Unit, Department of Immunoallergic and Respir
    May 25, 2022

    First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

    Recruiting
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC Trial in Worldwide (PF-06463922, Crizotinib)

    Active, not recruiting
    Has Results
    • ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
    • Fayetteville, Arkansas
    • +71 more
    Feb 16, 2022

    Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

    Not yet recruiting
    • Lung Cancer
    • Non-small Cell Lung Cancer
    • (no location specified)
    Jul 7, 2023

    NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

    Recruiting
    • NSCLC Stage IIIB
    • +4 more
    • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
    • Carboplatin + Pemetrexed + Atezolizumab
    • Angers, France
    • +30 more
    Jun 7, 2021

    NSCLC Trial in China (WX-0593 Tablets)

    Unknown status
    • Non-small Cell Lung Cancer
    • WX-0593 Tablets
    • Hefei, Anhui, China
    • +40 more
    Nov 17, 2020

    NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer ALK-positive
    • +4 more
    • Orange, California
    • +28 more
    Feb 15, 2022

    Non Small Cell Lung Cancer Trial in Worldwide (Taletrectinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Beverly Hills, California
    • +58 more
    Dec 13, 2022

    NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

    Terminated
    • Non-small Cell Lung Cancer
    • Davis, California
    • +1 more
    Dec 22, 2022

    Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

    Recruiting
    • Non Small Cell Lung Cancer
    • anti-PD-1 or anti-PD-L1
    • +2 more
    • Shanghai, China
      Oncology Department, Shanghai Chest Hospital
    Jul 26, 2022

    Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • HS-10365 capsules
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 22, 2023

    Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Tumor-infiltrating Lymphocytes (TIL)
    • +5 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022